A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 May 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DEPICT 1
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 07 Jun 2017 Biomarkers information updated
- 09 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.